A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon α-2b in advanced renal cell carcinoma: Major durable responses in a less highly selected patient population
J. I. Clark*, T. M. Kuzel, T. M. Lestingi, S. G. Fisher, P. Sorokin, B. Martone, M. Viola, J. A. Sosman
Dive into the research topics of 'A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon α-2b in advanced renal cell carcinoma: Major durable responses in a less highly selected patient population'. Together they form a unique fingerprint.